Published in Chest on October 01, 1992
Anticoagulation therapy for venous thromboembolism. MedGenMed (2004) 3.61
Diet as prophylaxis and treatment for venous thromboembolism? Theor Biol Med Model (2010) 0.83
Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Med Genomics (2014) 0.82
Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice. West J Med (1995) 0.81
Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs [corrected]. Pulm Circ (2012) 0.75
A systematic review of Cochrane anticoagulation reviews. Medscape J Med (2009) 0.75
Near-patient testing in primary care. Br J Gen Pract (2004) 0.75
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med (1993) 3.61
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med (1994) 3.44
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med (1993) 2.76
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Hemorrhagic complications of anticoagulant treatment. Chest (2001) 2.76
Prevention of venous thromboembolism. Chest (1995) 2.69
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol (1989) 2.22
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol (1966) 1.94
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med (2001) 1.93
Requirement of circadian genes for cocaine sensitization in Drosophila. Science (1999) 1.92
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol (1996) 1.91
Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr Biol (2000) 1.90
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation (1995) 1.90
Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88
Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst (1992) 1.87
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet (1970) 1.84
Prevention of venous thromboembolism. Chest (1992) 1.81
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
Low molecular weight heparin. Blood (1992) 1.74
The antidepressant-sensitive dopamine transporter in Drosophila melanogaster: a primordial carrier for catecholamines. Mol Pharmacol (2001) 1.73
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol (1986) 1.73
A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med (1999) 1.72
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 1.71
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol (1995) 1.66
Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. Br Med J (1968) 1.66
Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. N Engl J Med (1977) 1.66
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med (1982) 1.64
A randomized trial on the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty. Transfusion (1992) 1.62
The trace amine tyramine is essential for sensitization to cocaine in Drosophila. Curr Biol (1999) 1.60
Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J (1976) 1.59
The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med (1998) 1.58
Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost (1989) 1.58
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
Reevaluation of the sensitivity of impedance plethysmography for the detection of proximal deep vein thrombosis. Arch Intern Med (1994) 1.56
Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study. CMAJ (1999) 1.52
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med (1983) 1.51
Binding of a Drosophila POU-domain protein to a sequence element regulating gene expression in specific dopaminergic neurons. Nature (1990) 1.51
Regulated splicing produces different forms of dopa decarboxylase in the central nervous system and hypoderm of Drosophila melanogaster. EMBO J (1986) 1.50
Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation (1976) 1.50
The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost (1998) 1.49
Increased platelet adhesiveness in recurrent venous thrombosis and pulmonary embolism. Br Med J (1965) 1.48
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med (1996) 1.45
The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest (2001) 1.45
Molecular mapping of a gene cluster flanking the Drosophila Dopa decarboxylase gene. Genetics (1984) 1.44
Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost (1995) 1.44
Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med (1998) 1.43
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest (1978) 1.43
Heparin in the treatment of venous thrombo-embolic disease: administration, control and results. Med J Aust (1968) 1.41
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med (1995) 1.41
Conserved and sexually dimorphic behavioral responses to biogenic amines in decapitated Drosophila. Proc Natl Acad Sci U S A (1997) 1.41
Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med (1998) 1.40